[1]王鹏举,综述,陈茂,等.华法林相关性肾病[J].心血管病学进展,2016,(2):167-170.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.018]
　WANG Pengju,CHEN Mao.Warfarin-related Ephropathy[J].Advances in Cardiovascular Diseases,2016,(2):167-170.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.018]
点击复制

华法林相关性肾病()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年2期
页码:
167-170
栏目:
综述
出版日期:
2016-04-20

文章信息/Info

Title:
Warfarin-related Ephropathy
作者:
王鹏举; 综述; 陈茂; 审校
四川大学华西医院心内科,四川 成都 610041
Author(s):
WANG Pengju; CHEN Mao
Department of Cardiology,West China Hospital of Sichuan University,Chengdu 610041,Sichuan,China
关键词:
华法林;  华法林相关性肾病;  急性肾损伤
Keywords:
Warfarin;  Warfarin-related nephropathy;  Acute kidney injury
分类号:
R973+2
DOI:
10.16806/j.cnki.issn.1004-3934.2016.02.018
文献标志码:
A
摘要:
华法林相关性肾病是华法林治疗过程中一种并不少见的并发症,虽然该概念已提出15年,但其发病机制仍不清楚,同时也缺乏相对具有特异性、敏感性的临床诊断标准,现将华法林相关性肾病的研究进展进行综述。
Abstract:
Warfarin-related nephropathy is not a rare complication during treatment with warfarin.Although the concept has been proposed for 15 years, the etiology is still not clear.Correspondingly there is lack of diagnostic criteria characterized by well sensitivity and specificity in clinical practice.The present study reviews the etiology,clinical manifestation,risk factors and prognosis of warfarin-related nephropathy.

参考文献/References:

[1] Ageno W, Gallus AS, Wittkowsky A, et al.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2 Suppl): e44S-88S.
[2] Holbrook AM, Pereira JA, Labiris R, et al.Systematic overview of warfarin and its drug and food interactions[J].Arch Intern Med,2005,165(10):1095-1106.
[3] Brodsky SV, Nadasdy T, Rovin BH, et al.Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate[J].Kidney Int,2011,80(2):181-189.
[4] Reilly EB, Perry A, Fujita K,et al.Haematuria and anticoagulants[J].Lancet,1964,1(7332): 554.
[5] Abt AB, Carroll LE, Mohler JH.Thin basement membrane disease and acute renal failure secondary to gross hematuria and tubular necrosis[J].Am J Kidney Dis,2000,35(3): 533-536.
[6] Shafi ST, Negrete H, Roy P, et al.A case of dabigatran-associated acute renal failure[J].WMJ,2013,112(4):173-175; quiz 176.
[7] Lim AK, Campbell DA.Haematuria and acute kidney injury in elderly patients admitted to hospital with supratherapeutic warfarin anticoagulation[J].Int Urol Nephrol,2013,45(2): 561-570.
[8] Rizk DV,Warnock DG.Warfarin-related nephropathy:another newly recognized complication of an old drug[J].Kidney Int,2011,80(2):131-133.
[9] Nishio S, Tsuboi N, Kurashige M, et al.A case of acute kidney injury during warfarin therapy[J].Nihon Jinzo Gakkai Shi,2013,55(5):966-971.
[10] Zerah L,Brocheriou I,Galichon P,et al.Warfarin-related nephropathy:a case report[J].Rev Med Interne,2015,36(1):51-54.
[11] Brodsky SV, Satoskar A, Chen J, et al.Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts:a report of 9 cases[J].Am J Kidney Dis,2009,54(6):1121-1126.
[12] Ware K, Brodsky P, Satoskar AA, et al.Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation[J].J Am Soc Nephrol,2011,22(10): 1856-1862.
[13] Ware K, Qamri Z, Ozcan A, et al.N-acetylcysteine ameliorates acute kidney injury but not glomerular hemorrhage in an animal model of warfarin-related nephropathy[J].Am J Physiol Renal Physiol,2013,304(12):F1421-1427.
[14] Ozcan A, Ware K, Calomeni E, et al.5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy[J].Am J Nephrol,2012,35(4):356-364.
[15] Connolly SJ, Ezekowitz MD, Yusuf S, et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
[16] Giugliano RP, Ruff CT, Braunwald E, et al.Edoxaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2013,369(22):2093-2104.
[17] Patel MR, Mahaffey KW, Garg J, et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med,2011,365(10):883-891.
[18] Moeckel GW, Luciano RL, Brewster UC.Warfarin-related nephropathy in a patient with mild IgA nephropathy on dabigatran and aspirin[J].Clin Kidney J,2013,6(5):507-509.
[19] Ryan M, Ware K, Qamri Z, et al.Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats[J].Nephrol Dial Transplant,2014,29(12):2228-2234.
[20] Santos C, Gomes AM, Ventura A, et al.An unusual cause of glomerular hematuria and acute kidney injury in a chronic kidney disease patient during warfarin therapy[J].Nefrologia,2013,33(3):400-403.
[21] Mogyorosi A, Bradley B, Showalter A,et al.Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin[J].J Intern Med,1999,246(6): 599-602.
[22] Brodsky SV, Collins M, Park E, et al.Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease[J].Nephron Clin Pract,2010,115(2):c142-146.
[23] An JN, Ahn SY, Yoon CH, et al.The occurrence of warfarin-related nephropathy and effects on renal and patient outcomes in korean patients[J].PLoS One,2013,8(4): e57661.
[24] 冯双平,赵施竹.华法林相关肾病对肾脏的影响及患者预后[J].中国医师进修杂志,2013,36(24):50-52.
[25] Chang CC, Liou HH, Wu CL, et al.Warfarin slows deterioration of renal function in elderly patients with chronic kidney disease and atrial fibrillation[J].Clin Interv Aging,2013,8:523-529.
[26] Wheeler DS, Giugliano RP, Rangaswami JR.Anticoagulation-Related Nephropathy[J].J Thromb Haemost,2015,Dec 16.doi: 10.1111/jth.13229[Epub ahead of print].

相似文献/References:

[1]魏倩 梁岩.新型口服抗凝药物与维生素K拮抗剂相关的脑出血风险对比[J].心血管病学进展,2020,(5):441.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.001]
　WEI Qian,LIANG Yan.Comparison of Risk of Related Intracerebral Hemorrhage Between Non-vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists[J].Advances in Cardiovascular Diseases,2020,(2):441.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.001]
[2]徐风燕 孙飞龙.非瓣膜性心房颤动患者华法林抗凝质量的临床研究[J].心血管病学进展,2020,(8):868.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.021]
　XU Fengyan,SUN Longfei.(Department of Cardiology,Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University,Urumqi 831100,Xinjiang,China)[J].Advances in Cardiovascular Diseases,2020,(2):868.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.021]
[3]向珍贤 罗素新 黄毕.瓣膜性房颤和非瓣膜性房颤的区别和抗凝策略的差异[J].心血管病学进展,2023,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.010]
　XIANG ZhenxianLUO SuxinHUANG Bi.The Difference of Definition and Anticoagulation Therapy Strategies Between Valve and Non-valve Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.010]

备注/Memo

备注/Memo:
作者简介:王鹏举(1983—),住院医师,在读硕士,主要从事冠心病临床研究。Email:185920403@qq.com
更新日期/Last Update: 2016-03-25